@TidefallCapital You forgot organic growth on base biz (i.e. removing impacts of Vidspine and Datafusion) being ~ +5-7%. Company typically lets unprofitable contracts roll off post acq, making organic growth in y1 artificially low. EBITDA margins expanding 400bps to 42% too. Impressive stuff.
$BBU monetizing some underperforming assets by selling to retail investors at a much higher valuation from where BBU trades. Great outcome for BBU unitholders - not so sure about the retail investors. Y/y adj. EBITDA growth: CDK (-30%), DexCo (-23%) per Q1 filings. Probably nothing.
Reworked the headline a bit: “Retail investors now afforded the ‘opportunity’ to pay exorbitant fees to act as the liquidity provider for institutional investors as IPO window remains shut”
Another strong showing from $WCN.TO. Core pricing +6.3%, revs and adj. EBITDA above expectations. Core margins up 80bps. Canceled 1% of shares outstanding YTD and raised dividend 11.1%. Voluntary employee turnover improves for the 12th consecutive quarter.
No comment on the portfolio necessarily, but it’s undoubtedly been a difficult market for quality compounders. Eventually quality will matter again (as it always does), and the simple algo of above-inflation pricing + op leverage + cap allocation driving low teens FCF growth will be a winning formula. Until then, try to tune out the noise. Godspeed.
Don't underestimate the power of extreme decentralization. When comp is tied directly to ROIC, dealmakers are incentivized to get creative - VMS or not. Will be interesting to see the next chapter for $CSU.TO.
@ErnestWongBWM has been on top of this for some time now - and in my view, his work has been a genuine positive for the industry in Canada. Give credit where credit is due - competitor or not. Sadly, it's not how most advisors in Canada think today.
Alternative funds have been halting redemptions left and right recently - Bn's in everyday investors' $ tied up with no clear timeline to get it back. Far too much (in fees and in sleep) has been lost chasing novelty when all anyone needs is a simple mix of stocks/bonds/cash..
I get the “optimists make money” argument for just buying every 5bp dip in $QQQ and going to the beach. Yes, markets rise over time—no disputing that!
But I’d also wager many of these folks have never seen a client or family member in a brutal drawdown while simultaneously losing their job, forcing them to sell investments for income and wiping them out entirely. When it rains it pours! Unfortunate as it may be.
I've seen people forced into spending their retirement working a job they never wanted - AFTER they've sold a business and had a successful career - because of bad luck (unforeseen personal event) at precisely the wrong time (bad market).
For families who have already built a nest egg, whether the portfolio is flat or up 50% YTD means next to nothing. What matters is that its growing steadily over time above inflation + risk premium—at a pace that meets personal goals, funds the desired retirement lifestyle, and avoids the unforeseen bombs. What else really matters?
That's the difference between FinTwit and real people. (Though admittedly, I have a soft spot for watching FinTwit belligerence like the Zoomer guy from afar!)
@wlep Agree with you on the longer term margin expansion op - just disagree on the 'how' that some people are highlighting (i.e. aggressively cutting dev). Op leverage more likely to come from high incremental-margin organic product/feature rollouts imo
Disagree with the idea that margins will explode higher at $CSU.TO with AI replacing dev staff. A few of its top private competitors outsource dev work overseas and have for years. Most sellers hate it. Part of the value prop of selling to CSU is the promise to keep the team intact
Maybe not a specific example, but the whole ‘win by not losing’ approach of avoiding the bombs and controlling down-capture with *boring* names is pretty powerful in a LO acct (+ tax efficient) over time. Esp since we’re talking real humans that have real emotions & mouths to feed.
@partners_road All across the staples complex. Years of taking aggressive pricing on anemic volumes and shrinking packaging. Finally catching up. As it should. $PEP